Clinical trials: Insulin-Dependent Diabetes Mellitus
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
The purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin degludec) for at least 6 months.
- Trial name
- CAN-TREAT (NCT03674866)
- Testing
- Insulin degludec
- Where
- 32 sites in Canada
- Volunteers
- 662 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Non-Insulin-Dependent
Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas.
- Trial name
- NCT00071422
- Testing
- INGAP-Peptide
- Where
- 17 sites in United States
- Volunteers
- 126 people
- Sponsor
- Exsulin Corporation
Type 1 Diabetes Mellitus
Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes
The purpose of this study was to compare the pharmacokinetic (PK) response after inhaled insulin administration with 3 different inhalation regimens and with subcutaneous insulin administration.
- Trial name
- Samba-01 (NCT02713841)
- Testing
- inhaled human insulin (INH), sc insulin lispro (LIS)
- Volunteers
- 12 people
- Sponsor
- Dance Biopharm Inc.
Diabetes Mellitus Type 1
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*) administered subcutaneously to patients with type 1…
- Trial name
- NCT02916251
- Testing
- ZP4207(dasiglucagon) glucagon analogue, Glucagon (Native glucagon)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes Mellitus
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
- Trial name
- NCT06152042
- Testing
- BMF-219
- Where
- 11 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Biomea Fusion Inc.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This is a two-part trial, with three panels per part.
- Trial name
- NCT03095651
- Testing
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as…
- Trial name
- SWITCH 1 (NCT02034513)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 99 sites in United States, Poland and 1 more
- Volunteers
- 501 people
- Sponsor
- Novo Nordisk A/S
Pressure Ulcer, Foot Ulcer, Diabetic
Use of Santyl Within an Accountable Care Organization
This study is designed to assess the comparative effectiveness of SANTYL® versus standard of care in the treatment of pressure ulcers and diabetic foot ulcers within the continuum of care of an ACO.
- Trial name
- NCT02716519
- Testing
- Santyl, Standard Care
- Where
- United States
- Sponsor
- Smith & Nephew, Inc.
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Type 1 Diabetes
Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 Diabetes
This early feasibility first-in-human study is a prospective single-arm single-center study of Sigi insulin patch pump. After a 1st day and night under medical surveillance during a hotel stay, Sigi system will be evaluated…
- Trial name
- SigiFIH (NCT05973422)
- Testing
- SIGI Insulin Management System
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus Type 1
A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes
This crossover, glucose-clamp study will investigate the impact of different basal insulin infusion rates on glucose control employing insulin pumps with different insulin delivery regimen.
- Trial name
- NCT00772356
- Testing
- Accu-Chek Spirit Insulin Pump, Comparator insulin pump
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes
This trial was conducted in Europe, Middle East, North America and South America. The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart (NovoRapid®) versus human insulin (Actrapid®)…
- Trial name
- NCT00365170
- Testing
- human insulin, insulin aspart
- Where
- 95 sites in Argentina, Austria and 16 more
- Volunteers
- 419 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
The PSIQS Study - User Experience With Pro-Set
Open label, randomized 2-period cross-over study comparing two continuous subcutaneous insulin infusion sets ; MiniMed® Pro-set® with BD FlowSmart™ technology and MiniMed® Quick-set®
- Trial name
- NCT03242005
- Testing
- MiniMed® Pro-set®, MiniMed® Quick-set®
- Sponsor
- Becton, Dickinson and Company
Diabetes
SKAMo-2: the Real-life Test of Continuous Photoacoustic Signal by Neogly in Patients With Type I Diabetes
Diabetes is one of the very common and chronic diseases in the present world, which affects children and adults. Diabetes is characterized by hyperglycemia.
- Trial name
- NCT06035367
- Testing
- Non-invasive continuous monitoring device to record photoacoustic signal
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Eclypia
Islet Transplantation in Diabetes Mellitus Type 1
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
The objective of this clinical trial was: to assess whether Reparixin leads to improved transplant outcome as measured by glycaemic control following intra-hepatic infusion of pancreatic islets in patients with Type 1 diabetes…
- Trial name
- REP0211 (NCT01817959)
- Testing
- Reparixin
- Where
- 9 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00671008
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- Bosnia and Herzegovina
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Insulin Resistance
Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes
This study will investigate the safety and efficacy of the investigational use of the HydraSolve T2D™ System in improving blood glucose control and insulin resistance in patients with obesity (Class 1, BMI 30-39.9 kg/m2) and type…
- Trial name
- NCT03953963
- Testing
- HydraSolve T2D™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medality Medical
Diabetes Mellitus, Type 1
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants…
- Trial name
- NCT05184868
- Testing
- AT247, NovoLog, Fiasp
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arecor Limited
Type 1 Diabetes
DIabetic Retinopathy Candesartan Trials.
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252720)
- Testing
- candesartan
- Volunteers
- 1,850 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.